APP (Amyloid Beta Precursor Protein)

Thus, seven γ-secretase inhibitor candidates with favorable affinity scores capable of providing stable interactions and thereby having the potential to disrupt the APH1:PS1 assembly were identified. This approach, which overcomes the challenges of targeting the transmembrane catalytic domain, is based on the inhibition of subunit assembly and presents promising candidates for future experimental studies.

Expert opinion/Commentary: These antibodies provide valuable new tools for mechanistic studies of LRP8. By improving the investigation of LRP8 processing and localization, they may facilitate a better understanding of its role in neurodegeneration and cancer.

Our findings indicate that TNFRSF21 is a pivotal regulator of epithelial keratinization and tight junction integrity in oral epithelial keratinocytes. Targeting TNFRSF21 may represent a novel therapeutic strategy to restore oral epithelial function.

In the hippocampus, H2 upregulated nuclear factor erythroid 2-related factor 2 (NRF2), attenuated nuclear factor kappa B (NF-κB) activation, reduced the BAX/BCL-2 ratio, preserved neuronal nuclei (NEUN) expression, and decreased hippocampal Aβ42 burden. Collectively, these findings indicate that H2 inhalation confers multi-faceted neuroprotection in 5xFAD mice by restoring redox homeostasis, suppressing inflammation, improving mitochondrial function, and limiting Aβ accumulation.

Strikingly, its combination with the immune checkpoint inhibitor Nivolumab synergistically boosted antitumor immunity and reshaped the immunosuppressive TME. These findings uncover the APP-CD74 axis as a novel immunoregulatory pathway in GC and provide a nanotherapeutic strategy leveraging macrophage plasticity to overcome immune resistance and enhance immunotherapeutic efficacy.

This study is the first to integrate bibliometric and bioinformatics methods, revealing the macro-level trends in OP-ATG research and the molecular mechanisms underlying OP-LP crossover. It successfully identified five key OP-LP targets, providing a new perspective for understanding OP mechanisms and developing targeted therapies.

Overall, arsenic promotes intracellular Aβ(1-42) accumulation, possibly through the upregulation of APP and a decrease in the Aβ-degrading enzyme, NEP, and extracellular Aβ aggregation by AChE upregulation. As both Aβ intracellular accumulation and extracellular aggregation play pivotal roles in AD, our findings may provide insightful mechanistic links between arsenic and AD.

Furthermore, E4 modulated the expression of key mitochondrial genes, specifically upregulating the phosphate carrier SLC25A23 while downregulating the complex I subunit NDUFA1. In conclusion, E4 improves mitochondrial health and supports neuronal integrity via a multi-receptor mechanism, highlighting its potential as a safe neuroprotective therapy for AD.

These findings support a competing endogenous RNA (ceRNA) model in which LIMASI sequesters pro-inflammatory miRNAs to modulate neuroinflammatory gene networks. Together, our data identify LIMASI as a putative ceRNA strongly associated with AD-related neuroinflammation and suggest that targeting LIMASI may represent a novel strategy to attenuate neuroinflammatory signaling and potentially slow AD-associated neurodegeneration.

Furthermore, G2CT rescues cognitive deficits in male and female 5×FAD AD mouse models, without detectable alterations in amyloid precursor protein processing or amyloid-beta (Aβ) production under the experimental conditions used. These findings identify the GluA2-AP2M1 interaction as a critical mechanism of early synaptic dysfunction and highlight a therapeutic strategy for AD that acts downstream of amyloid-β signaling and ameliorates synaptic and cognitive deficits without altering amyloid pathology.

This study is the first to integrate bibliometric and bioinformatics methods, revealing the macro-level trends in OP-ATG research and the molecular mechanisms underlying OP-LP crossover. It successfully identified five key OP-LP targets, providing a new perspective for understanding OP mechanisms and developing targeted therapies.

Deleting the lysosomal lipid hydrolase NAAA in oligodendrocytes prevents both injury-induced Aβ production and chronic pain development. The findings identify an unexpected mechanistic link between chronic pain and Alzheimer's-like neurodegeneration, positioning Aβ as a target for therapeutic intervention.